Senzime obtains US patent
Uppsala, August 9, 2017. Senzime AB (publ) is awarded a U.S. patent for its TetraSens disposable electrodes. With its unique design, the TetraSens enables fast application and effective function. The electrodes are used in conjunction with Senzime's neuromuscular monitoring system, the TetraGraph, which contributes to effective, continuous monitoring of patients undergoing anesthesia and surgical muscle relaxation. The TetraGraph, via the interfaced TetraSens electrodes, makes it possible to easily and objectively determine the optimal dose of neuromuscular blocking drugs administered during the procedure, and to establish the appropriate time when it is safe to wake the patient after surgery and allow spontaneous breathing without the help of a ventilator.
Every year, over 70 million patients undergo surgery and receive muscle relaxant drugs; research has shown that over 30 percent of patients suffer from postoperative complications if objective neuromuscular monitoring is not used. The TetraGraph is an inexpensive and easy-to-use solution that helps clinicians avoid postoperative complications in their patients.
“Senzime develops products to reduce complications associated with operations, increase patient safety and contribute to lower healthcare costs. The granted patent for TetraSens strengthens our competitiveness and proves our innovative power. Senzime is facing a broad market introduction and we are looking forward to a continued eventful development in 2017”, says Lena Söderström, CEO Senzime.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on August 9, 2017.